At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Pre-Mkt 02-05 04:15:07 EST
15.03
-0.34
-2.21%
盘前15.01
-0.02-0.13%
04:03 EST
High15.57Low14.47Vol1.59M
Open15.26D1 Closing15.37Amplitude7.16%
Mkt Cap1.07BTradable Cap607.45MTotal Shares71.37M
T/O23.76MT/O Rate3.93%Tradable Shares40.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MoonLake Immunotherap Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-03 21:16
MoonLake Immunotherap Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
FDA Grants Fast Track Designation to MoonLake’s Sonelokimab for Palmoplantar Pustulosis
Reuters  ·  02-02 21:00
FDA Grants Fast Track Designation to MoonLake’s Sonelokimab for Palmoplantar Pustulosis
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Moderna (MRNA)
TIPRANKS  ·  01-20
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Moderna (MRNA)
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials
Simply Wall St.  ·  01-19
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
TIPRANKS  ·  01-15
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
MoonLake Immunotherapeutics Shares Rise After BTIG Upgrade
MT Newswires Live  ·  01-10
MoonLake Immunotherapeutics Shares Rise After BTIG Upgrade
BTIG Research Upgrades MoonLake Immunotherapeutics to Buy From Neutral, $24 Price Target
MT Newswires Live  ·  01-09
BTIG Research Upgrades MoonLake Immunotherapeutics to Buy From Neutral, $24 Price Target
MoonLake Immunotherapeutics : Btig Raises to Buy From Neutral
THOMSON REUTERS  ·  01-09
MoonLake Immunotherapeutics : Btig Raises to Buy From Neutral
MoonLake price target raised to $32 from $26 at H.C. Wainwright
TIPRANKS  ·  01-09
MoonLake price target raised to $32 from $26 at H.C. Wainwright
MoonLake Immunotherap Raised to Buy From Neutral by BTIG
Dow Jones  ·  01-09
MoonLake Immunotherap Raised to Buy From Neutral by BTIG
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
TIPRANKS  ·  01-09
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap
Reuters  ·  01-09
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap
MoonLake Immunotherapeutics Up Nearly 26%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk
Dow Jones  ·  01-09
MoonLake Immunotherapeutics Up Nearly 26%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
TIPRANKS  ·  01-08
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating
MoonLake Immunotherapeutics Shares Soar 32..9% as US FDA Clears Path for Skin Disease Drug Filing
THOMSON REUTERS  ·  01-08
MoonLake Immunotherapeutics Shares Soar 32..9% as US FDA Clears Path for Skin Disease Drug Filing
BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
Reuters  ·  01-08
BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA
Reuters  ·  01-08
Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA
BUZZ-MoonLake soars as FDA clears path for skin disease drug filing
Reuters  ·  01-08
BUZZ-MoonLake soars as FDA clears path for skin disease drug filing
BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA
Reuters  ·  01-08
BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA
MoonLake Immunotherapeutics Shares Rise 35% Premarket After Meeting With US FDA Regarding Co's Skin Disease Drug Marketing Application
THOMSON REUTERS  ·  01-08
MoonLake Immunotherapeutics Shares Rise 35% Premarket After Meeting With US FDA Regarding Co's Skin Disease Drug Marketing Application

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--